Canaccord Genuity Group Issues Positive Forecast for Diaceutics (LON:DXRX) Stock Price

Diaceutics (LON:DXRX) had its price target hoisted by stock analysts at Canaccord Genuity Group from GBX 215 to GBX 216 in a report issued on Thursday,Digital Look reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 42.29% from the company’s previous close.

Diaceutics Price Performance

LON DXRX opened at GBX 151.80 on Thursday. Diaceutics has a one year low of GBX 112.25 and a one year high of GBX 180. The stock has a 50-day moving average of GBX 161.50 and a 200 day moving average of GBX 153.70. The company has a market capitalization of £128.47 million, a price-to-earnings ratio of -84.33 and a beta of 0.92. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43.

Diaceutics (LON:DXRX) last released its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. The firm had revenue of GBX 3,844 million for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. On average, sell-side analysts forecast that Diaceutics will post 1.0107919 EPS for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.